06.27.2025
Science
Software-Enhanced Drugs
Breast Cancer
Why Cancer Scripts of the Future Will Include an App
By Shaheen Lakhan, MD, PhD, FAAN
Chief Medical Officer
Where science meetssoftware.
Software as treatment.
Delivered to your phone.
Prescribed by your physician.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.
Digital treatments, tangible outcomes.
We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.
Click SE
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.
One powerful platform. Many ways to treat disease.
Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.
Latest at Click
Recent publications
Collaborators
By embracing collaborations that build on our unique areas of expertise, we’re powering a new era of medicine.
Collaborating on:
CT-152
Collaborating on:
CT-155
Collaborating on:
CT-156
Contact
Join us in our journey to raise the bar of modern medicine with software as treatments.
Join usStay up to date with news and updates
Click Therapeutics Today
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.